Ezetimibe clinical trials
Also written Zetia, Ezetrol, MK0653 and SCH 58235.
Its developmentBy 16 companies, company by company97 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.Counted the way a researcher would: Ezetimibe with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Ezetimibe is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Ezetimibe studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 Oct 2002 · ZETIA · NDA 021445 (FDA, Drugs@FDA)
- European Union
- 27 Mar 2020 · Nustendi · EMEA/H/C/004959 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
208 studies that test it; most in 2005 (22)
| Year | Studies |
|---|---|
| 2000 | 3 |
| 2001 | 6 |
| 2002 | 2 |
| 2003 | 16 |
| 2004 | 12 |
| 2005 | 22 |
| 2006 | 12 |
| 2007 | 21 |
| 2008 | 7 |
| 2009 | 13 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 8 |
| 2014 | 8 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 8 |
| 2018 | 7 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 7 |
| 2025 | 8 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 114 · Other 94
Organon and Co (68) · Chong Kun Dang Pharmaceutical (7) · Daiichi Sankyo (6) · NewAmsterdam Pharma (3) · Sanofi (3) · Yonsei University (3) · University of California, San Diego (3) · University of Sao Paulo (3)
Often tested with
Tested in the same studies.
Simvastatin (43) · Rosuvastatin (30) · Atorvastatin (26) · Statins (12) · Bempedoic acid (10) · Telmisartan (9) · Niacin (6) · CKD-348 (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test Ezetimibe.
- Dec 2026Ezetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial"Not applicable · Cairo University
- Jan 2027LDL Cholesterol Reduction Following Ezetimibe InitiationPhase 4 · Universidade do Porto
- Jul 2027Cholesterol Lowering and Residual Risk in Diabetes, Type 1Phase 4 · NYU Langone Health
- Nov 2027Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque StabilizationPhase 4 · Korea University Anam Hospital
Studies
Open first, then newest update. How each study uses Ezetimibe is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 208
- A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular EventsRecruitingPhase 3Daiichi SankyoNCT07474649Written as EzetimibeHow we know
- Aggressive Lipid Lowering Therapy in ICI-Treated MelanomaRecruitingNot applicableUniversity of Colorado, DenverNCT07704918Written as Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)How we know
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1RecruitingPhase 4NYU Langone HealthNCT05641753Written as Ezetimibe TabletsHow we know
- Ezetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial"RecruitingNot applicableCairo UniversityNCT04701242Written as Ezetimibe 10mgHow we know
- LDL Cholesterol Reduction Following Ezetimibe InitiationRecruitingPhase 4Universidade do PortoNCT07839741Written as EzetimibeHow we know
- Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion StrokeRecruitingNot applicableSeoul National University HospitalNCT06649240Written as Statins and/or EzetimibeHow we know
- Ezetimibe for Arrhythmia Recurrence After AF AblationNot yet recruitingPhase 4Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07752758Written as EzetimibeHow we know
- Livalozet Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary InterventionNot yet recruitingNot applicableSamsung Medical CenterNCT07626840Written as Pitavastatin/ezetimibeHow we know
- Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary SyndromeNot yet recruitingPhase 4Punjab Institute of CardologyNCT07508254Written as Ezetimibe 10 mgHow we know
- Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate CancerRecruitingPhase 2Cedars-Sinai Medical CenterNCT06437574Written as EzetimibeHow we know
- Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With AtherosclerosisRecruitingPhase 2Chang Gung Memorial HospitalNCT07307989Written as statin + ezetimibeHow we know
- Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMIRecruitingPhase 4Kiyuk Chang, MD,PhDNCT04499859Written as Ezetimibe 10mg + Rosuvastatin 5mgHow we know
- To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary HypercholesterolemiaEnrolling by invitationPhase 3Hyundai PharmNCT06646354Written as Ezetimibe/Rosuvastatin/Candesartan/AmlodipineHow we know
- Effect of PCSK9 Inhibitors on Calcific Aortic Valve StenosisRecruitingPhase 3Beijing Anzhen HospitalNCT04968509Written as PCSK9 inhibitors and statins with or without ezetimibeHow we know
- Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant PatientsNot yet recruitingPhase 4University of SalernoNCT06381947Written as Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibeHow we know
- Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)Not yet recruitingNot applicableJena University HospitalNCT05587621Written as statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiranHow we know
- A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in StrokeRecruitingPhase 4Korea University Anam HospitalNCT05884502Written as combination of high-dose rosuvastatin and ezetimibeHow we know
- Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque StabilizationActive, not recruitingPhase 4Korea University Anam HospitalNCT06767345Written as Rosuvastatin/ezetimibeHow we know
- Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL CholesterolCompletedPhase 4Bahria UniversityNCT07255820Written as Rosuvastatin + EzetimibeHow we know
- Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High CholesterolCompletedPhase 3Celltrion Pharm, Inc.NCT07564726Written as Ezetimibe/RosuvastatinHow we know
See all 208 studies that test Ezetimibe →
Given beside what is tested · 33 — Ezetimibe is usual care or a partner of the new treatment
- Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary SyndromeNot yet recruitingPhase 4Seoul National University Bundang HospitalNCT07799779Written as EzetimibeHow we know
- Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary SyndromeRecruitingPhase 4Taipei Medical University HospitalNCT07824323Written as EzetimibeHow we know
- Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2x2 Factorial, Randomized, Parallel-Group, Multicenter TrialNot yet recruitingPhase 4Peking Union Medical College HospitalNCT07605130Written as EzetimibeHow we know
- A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.CompletedPhase 1AstraZenecaNCT06742853Written as EzetimibeHow we know
- Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCICompletedPhase 4Yonsei UniversityNCT05661552Written as Ezetimibe 10mgHow we know
- Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)CompletedPhase 3Organon and CoNCT03867318Written as EzetimibeHow we know
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348CompletedPhase 1Chong Kun Dang PharmaceuticalNCT04660370Written as CKD-828, D097, D337How we know
- A Study of PCSK9 Inhibitor AK102 in Patients With HypercholesterolemiaCompletedPhase 2AkesoNCT04358432Written as Statins and/or EzetimibeHow we know
- A Long-term Study of AK102 in Patients With HypercholesterolemiaCompletedPhase 2AkesoNCT04173403Written as Statins and/or EzetimibeHow we know
- A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFHCompletedPhase 2AkesoNCT03933293Written as EzetimibeHow we know
- A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedPhase 2AkesoNCT04173793Written as Statins and/or EzetimibeHow we know
- Durable Effect of PCSK9 Antibody CompARed wiTh placEbo StudyCompletedPhase 3AmgenNCT01516879Written as EzetimibeHow we know
- Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)CompletedPhase 3SanofiNCT02476006Written as ezetimibeHow we know
- Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)CompletedPhase 3Organon and CoNCT03885921Written as EzetimibeHow we know
- A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348CompletedPhase 1Chong Kun Dang PharmaceuticalNCT04587206Written as CKD-828, D097, D337How we know
- Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With HypercholesterolemiaStatus unknownPhase 4Policlinico Casilino ASL RMBNCT04659525Written as EzetimibeHow we know
- Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant PatientsStatus unknownPhase 4Policlinico Casilino ASL RMBNCT04397653Written as EzetimibeHow we know
- Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)CompletedPhase 3Esperion Therapeutics, Inc.NCT03001076Written as EzetimibeHow we know
- A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin TherapyCompletedPhase 3Esperion Therapeutics, Inc.NCT03337308Written as Bempedoic Acid + Ezetimibe Fixed-Dose CombinationHow we know
- Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-CCompletedPhase 2Esperion Therapeutics, Inc.NCT03051100Written as Ezetimibe 10mgHow we know
Showing 20 of 33.
As the comparator · 37 — what is tested is compared with Ezetimibe
- Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)Not yet recruitingNot applicableYun Dai ChenNCT06854523Written as Statin+ezetimibeHow we know
- Statin and Bone HealthEnrolling by invitationPhase 4The University of Hong KongNCT05613400Written as Ezetimibe 10mgHow we know
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)CompletedPhase 3Merck Sharp & Dohme LLCNCT06450366Written as EzetimibeHow we know
- Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.CompletedPhase 3Novartis PharmaceuticalsNCT05763875Written as EzetimibeHow we know
- Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)TerminatedPhase 4Organon and CoNCT00651378Written as Ezetimibe + AtorvastatinHow we know
- Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)CompletedPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT05795517Written as Ezetimibe 10mgHow we know
- Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular DiseaseCompletedPhase 4Korea University Anam HospitalNCT04826354Written as Rosuvastatin and EzetimibeHow we know
- Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2CompletedPhase 3AmgenNCT01763827Written as EzetimibeHow we know
- LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2CompletedPhase 3AmgenNCT01763866Written as EzetimibeHow we know
- Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid LevelsCompletedPhase 2AmgenNCT01375777Written as EzetimibeHow we know
- A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221ACompletedPhase 3Addpharma Inc.NCT05131997Written as AD-221BHow we know
- Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed DyslipidemiaCompletedPhase 3Orient Pharma Co., Ltd.NCT04643093Written as EzetimibeHow we know
- A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)CompletedPhase 1Organon and CoNCT01236430Written as EzetimibeHow we know
- Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV DiseaseStatus unknownNot applicableCambridge University Hospitals NHS Foundation TrustNCT03355027Written as Ezetimibe 10Mg TabletHow we know
- A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and DyslipidemiaCompletedPhase 3Hanmi Pharmaceutical Company LimitedNCT04074551Written as Rosuvastatin and EzetimibeHow we know
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4CompletedPhase 3AmgenNCT02634580Written as EzetimibeHow we know
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2CompletedPhase 3AmgenNCT01763905Written as EzetimibeHow we know
- Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)CompletedPhase 3Regeneron PharmaceuticalsNCT01709513Written as EzetimibeHow we know
- Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-CCompletedPhase 2Esperion Therapeutics, Inc.NCT03531905Written as Ezetimibe 10 mg Oral TabletHow we know
- A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin TherapyCompletedPhase 3Esperion Therapeutics, Inc.NCT03337308Written as Bempedoic Acid + Ezetimibe Fixed-Dose CombinationHow we know
Showing 20 of 37.
What changed recently
From the registry's own updates since Oct 21, 2026.
Started recruiting1
Codes
What other systems call Ezetimibe · ClinicalTrials.gg INT006574
- MeSH (NLM) D000069438EzetimibeConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) EOR26LQQ24EZETIMIBEConfirmed FDA, NLM, Wikidata
- RxNorm 341248Confirmed FDA, Wikidata
- Wikidata Q417997ezetimibeConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47529EzetimibeOne source FDA
- DrugBank DB00973One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069438 | Ezetimibe | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | EOR26LQQ24 | EZETIMIBE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 341248 | — | Confirmed FDA, Wikidata |
| Wikidata | Q417997 | ezetimibe | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47529 | Ezetimibe | One source FDA |
| DrugBank | DB00973 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.